Steroid-induced glaucoma - borderline

Summary

Steroid-induced glaucoma - borderline (MONDO:0001996) is a disease and 1 clinical trial. Top therapeutic interventions include ranibizumab. A subtype of borderline glaucoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	steroid-induced glaucoma - borderline
Mondo ID	MONDO:0001996
DOID	DOID:14548
SNOMED CT	302895007
UMLS	C0339572
MedGen	573233
Is cancer (heuristic)	no

Also known as: steroid responders borderline glaucoma

Disease family

This is a subtype of borderline glaucoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › glaucoma › borderline glaucoma › steroid-induced glaucoma - borderline

Related subtypes (1): anatomical narrow angle borderline glaucoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01564108	PHASE2	COMPLETED	The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RANIBIZUMAB	4	1